The Regulator

230 billion dollars: that is the fraud the White House says it has uncovered across federal programs since January 2025, and health care, not any other single sector, supplied the single biggest piece of the tally. Vice President JD Vance and the White House Task Force to Eliminate Fraud launched Fraud.gov, branded “The Fraud Ledger,” on August 6, 2026, a public site tracking what the administration says is $230 billion in identified fraud, waste and improper payments and $56 billion in payments actually stopped since the task force’s creation. The Department of Health and Human Services accounts for the largest share by dollar amount: the ledger credits HHS programs with $96 billion in fraud uncovered and $46 billion stopped, on top of enforcement actions the administration says have suspended 1,076 hospices from Medicare in California alone, halted $1.4 billion in home health and hospice funding nationwide, frozen new Medicare hospice enrollments, and pushed nearly 60 percent of Minnesota’s Medicaid providers off the program’s rolls. Confidence: Medium. The White House’s own release states the dollar figures and actions directly, but federal auditors have separately cautioned that improper payments are not the same as proven fraud, and the administration’s tally has not been independently audited. Sources: Fraud.gov: Track the Trump Administration’s Relentless War on Fraud, The White House, White House fraud tracker exposes nearly $300 billion tab as health programs take center stage, Just the News.

10 million dollars: that is what Texas Children’s Hospital agreed to pay the state over Medicaid billing for gender-transition care a 2023 state law banned, in a settlement that also forces the country’s first hospital-run detransition clinic to open by the end of October. Texas Attorney General Ken Paxton’s office finalized the settlement in early August 2026, resolving allegations first filed in February that the hospital used false diagnosis codes to bill Texas Medicaid for gender-transition interventions after Senate Bill 14 banned them for minors. Of the $10 million total, $8,576,000 goes to the state; the hospital must permanently revoke the medical staff privileges of five physicians and never rehire or credential them again, must fund free care for affected patients for five years, and must open the clinic within 90 days of finalization, a deadline that lands at the end of October 2026. Confidence: Medium. This run could not independently retrieve the Attorney General’s own settlement pages, which returned access errors, but the dollar figures, deadline and terms are corroborated directly across multiple outlets that reviewed the settlement document. Sources: Attorney General Paxton Finalizes Historic Settlement with Texas Children’s Hospital, Texas Attorney General, Texas Children’s Hospital to Open First Detransition Clinic Under Paxton Settlement, The Daily Signal.

14.1 million dollars: that is what a Jacksonville, Florida Medicare Advantage provider will pay after prosecutors said it pressured coders to invent diagnoses that inflated its federal payments. The Department of Justice announced August 3, 2026 that Complete Health Partners Holdings agreed to pay $14,100,000 to resolve a False Claims Act suit alleging that between 2020 and 2023 the company caused the submission of diagnosis codes for substance abuse and mental health conditions that were not clinically valid, not supported by medical records and not part of patients’ actual care, inflating the risk scores that determine how much Medicare Advantage plans get paid per enrollee. A whistleblower, former employee Karen Bowers, will collect roughly $2,467,500 of the settlement under the False Claims Act’s qui tam provisions. Confidence: High. The Department of Health and Human Services Office of Inspector General’s own enforcement posting states the settlement amount, dates and allegations directly. Sources: Medicare Advantage Provider Complete Health to Pay $14,100,000 to Settle False Claims Act Suit, HHS Office of Inspector General, Complete Health to pay $14M to settle Medicare Advantage fraud allegations, Healthcare Dive.

October 9, 2026: that is the deadline for public comment on an FDA plan that would let makers of 3D mammography machines skip the government’s slowest, most expensive device approval track. The Food and Drug Administration published a proposed rule August 10, 2026 (Docket No. FDA-2026-N-7630) to reclassify digital breast tomosynthesis systems, the three-dimensional imaging technology increasingly standard for breast cancer screening, from Class III, which requires full premarket approval, to Class II, which requires the faster premarket notification process paired with new special controls the agency is proposing alongside the reclassification. FDA took a comparable step for 2D digital mammography systems in the 2010s; trade coverage of that shift put the resulting drop in typical approval timelines at more than two years down to a few months, with costs falling from the hundreds of thousands of dollars to the tens of thousands, the closest available benchmark for device makers if this proposal finalizes. Confidence: High on the proposed rule’s terms and deadline, stated directly in the Federal Register filing; Low on the cost and timeline comparison, which reflects one industry account of a related but separate past reclassification, not a claim in this rule itself. Sources: Radiology Devices; Reclassification of Digital Breast Tomosynthesis System, Federal Register.

2 months: that is how fast Medicare could begin covering a new breakthrough medical device under a pathway CMS detailed further this week, down from roughly a year or more today. The Centers for Medicare and Medicaid Services released a detailed procedural notice, CMS-3487-NC, on August 7, 2026 for the Regulatory Alignment for Predictable and Immediate Device coverage pathway, first announced with the Food and Drug Administration in April 2026, which is scheduled for Federal Register publication August 11 and opens a 60-day comment period. Under RAPID, CMS commits to issuing a proposed national coverage determination the same day an eligible FDA-designated Class II or Class III breakthrough device receives market authorization, triggering the statutory 30-day comment period immediately rather than waiting for a separate coverage review to begin, with CMS staff engaging device makers earlier in FDA’s review process to flag which clinical outcomes matter for Medicare coverage. Confidence: High. CMS’s own notice and the American Hospital Association’s direct summary of it state the mechanics, dates and deadlines. Sources: CMS Releases Fact Sheet on Regulatory Alignment for Predictable and Immediate Device Coverage Pathway, Centers for Medicare and Medicaid Services, CMS releases notice on pathway for expediting access to certain medical devices for Medicare beneficiaries, American Hospital Association.